| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 293 | 2024 | 3021 | 22.060 |
Why?
|
| Genes, BRCA1 | 86 | 2023 | 192 | 9.930 |
Why?
|
| Genes, BRCA2 | 72 | 2023 | 161 | 8.270 |
Why?
|
| Genetic Predisposition to Disease | 140 | 2023 | 2360 | 7.910 |
Why?
|
| BRCA1 Protein | 61 | 2023 | 205 | 7.910 |
Why?
|
| BRCA2 Protein | 52 | 2023 | 161 | 6.770 |
Why?
|
| Genetic Testing | 52 | 2023 | 541 | 5.560 |
Why?
|
| Ovarian Neoplasms | 56 | 2023 | 771 | 5.050 |
Why?
|
| Mutation | 114 | 2023 | 4164 | 4.980 |
Why?
|
| Triple Negative Breast Neoplasms | 15 | 2023 | 168 | 4.880 |
Why?
|
| Germ-Line Mutation | 42 | 2022 | 347 | 4.390 |
Why?
|
| Nigeria | 41 | 2024 | 157 | 3.730 |
Why?
|
| Female | 375 | 2024 | 46529 | 3.690 |
Why?
|
| Humans | 458 | 2024 | 89864 | 3.000 |
Why?
|
| Polymorphism, Single Nucleotide | 73 | 2023 | 2414 | 2.840 |
Why?
|
| Neoplasms | 36 | 2023 | 3062 | 2.770 |
Why?
|
| Middle Aged | 207 | 2024 | 26103 | 2.600 |
Why?
|
| Biomarkers, Tumor | 30 | 2021 | 1542 | 2.470 |
Why?
|
| Genomics | 10 | 2020 | 776 | 2.360 |
Why?
|
| Heterozygote | 50 | 2020 | 373 | 2.320 |
Why?
|
| Adult | 192 | 2024 | 26784 | 2.220 |
Why?
|
| Genetic Counseling | 18 | 2023 | 102 | 2.100 |
Why?
|
| Genome-Wide Association Study | 39 | 2023 | 1689 | 2.020 |
Why?
|
| Receptors, Estrogen | 27 | 2022 | 394 | 1.980 |
Why?
|
| Receptors, Progesterone | 16 | 2018 | 175 | 1.940 |
Why?
|
| Carcinoma, Ductal, Breast | 10 | 2021 | 160 | 1.880 |
Why?
|
| Chromosomes, Human, Pair 9 | 21 | 2016 | 80 | 1.790 |
Why?
|
| Receptor, ErbB-2 | 21 | 2023 | 247 | 1.770 |
Why?
|
| Health Status Disparities | 6 | 2023 | 191 | 1.740 |
Why?
|
| Aged | 124 | 2024 | 19230 | 1.570 |
Why?
|
| Risk Factors | 83 | 2024 | 5548 | 1.550 |
Why?
|
| Gene Expression Regulation, Neoplastic | 26 | 2021 | 1283 | 1.530 |
Why?
|
| Ovariectomy | 18 | 2022 | 82 | 1.490 |
Why?
|
| Case-Control Studies | 55 | 2024 | 1864 | 1.480 |
Why?
|
| Glucuronosyltransferase | 9 | 2014 | 186 | 1.440 |
Why?
|
| Risk Assessment | 39 | 2021 | 2324 | 1.410 |
Why?
|
| Alleles | 29 | 2021 | 1139 | 1.390 |
Why?
|
| DNA Methylation | 12 | 2018 | 664 | 1.380 |
Why?
|
| Estrogen Receptor alpha | 10 | 2017 | 148 | 1.330 |
Why?
|
| Breast | 19 | 2023 | 292 | 1.320 |
Why?
|
| Precision Medicine | 6 | 2023 | 413 | 1.250 |
Why?
|
| Promoter Regions, Genetic | 16 | 2019 | 961 | 1.240 |
Why?
|
| Breast Neoplasms, Male | 9 | 2019 | 31 | 1.220 |
Why?
|
| Neoadjuvant Therapy | 10 | 2023 | 376 | 1.210 |
Why?
|
| Mammography | 15 | 2018 | 475 | 1.210 |
Why?
|
| Early Detection of Cancer | 8 | 2019 | 419 | 1.200 |
Why?
|
| Colorectal Neoplasms | 11 | 2019 | 979 | 1.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2017 | 539 | 1.160 |
Why?
|
| Prognosis | 45 | 2023 | 3789 | 1.160 |
Why?
|
| Health Services Accessibility | 7 | 2021 | 435 | 1.150 |
Why?
|
| Genotype | 36 | 2023 | 1853 | 1.110 |
Why?
|
| Tumor Suppressor Proteins | 9 | 2020 | 289 | 1.100 |
Why?
|
| Neoplasm Staging | 26 | 2023 | 2000 | 1.090 |
Why?
|
| Tamoxifen | 7 | 2023 | 168 | 1.060 |
Why?
|
| Body Height | 5 | 2021 | 100 | 1.060 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2020 | 3468 | 1.050 |
Why?
|
| Neoplasms, Second Primary | 11 | 2014 | 260 | 1.040 |
Why?
|
| Up-Regulation | 4 | 2018 | 726 | 1.020 |
Why?
|
| Mass Screening | 7 | 2018 | 645 | 1.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 6 | 2015 | 126 | 1.010 |
Why?
|
| Chromosome Deletion | 13 | 2001 | 227 | 1.000 |
Why?
|
| Chromosome Aberrations | 9 | 2014 | 386 | 1.000 |
Why?
|
| Gene Expression Profiling | 17 | 2021 | 1452 | 1.000 |
Why?
|
| Neoplasm Proteins | 10 | 2019 | 538 | 0.970 |
Why?
|
| Aged, 80 and over | 47 | 2023 | 6779 | 0.970 |
Why?
|
| Paclitaxel | 8 | 2019 | 474 | 0.930 |
Why?
|
| Mastectomy | 13 | 2023 | 246 | 0.930 |
Why?
|
| Jews | 6 | 2018 | 42 | 0.920 |
Why?
|
| DNA Mutational Analysis | 18 | 2021 | 529 | 0.910 |
Why?
|
| Genetic Services | 3 | 2023 | 7 | 0.900 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2022 | 117 | 0.890 |
Why?
|
| United States | 32 | 2023 | 7094 | 0.890 |
Why?
|
| Cell Line, Tumor | 25 | 2021 | 2583 | 0.870 |
Why?
|
| Medical Oncology | 7 | 2021 | 384 | 0.850 |
Why?
|
| Cohort Studies | 31 | 2023 | 2886 | 0.830 |
Why?
|
| Ubiquitin-Protein Ligases | 6 | 2020 | 173 | 0.830 |
Why?
|
| Parity | 5 | 2015 | 97 | 0.830 |
Why?
|
| Neoplasms, Basal Cell | 3 | 2018 | 9 | 0.820 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2020 | 2505 | 0.820 |
Why?
|
| Founder Effect | 6 | 2018 | 104 | 0.820 |
Why?
|
| Breast Feeding | 3 | 2020 | 105 | 0.810 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2019 | 36 | 0.810 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2023 | 1350 | 0.800 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2022 | 412 | 0.800 |
Why?
|
| Capacity Building | 4 | 2020 | 12 | 0.790 |
Why?
|
| Pancreatic Neoplasms | 6 | 2019 | 684 | 0.790 |
Why?
|
| Epigenesis, Genetic | 8 | 2018 | 521 | 0.780 |
Why?
|
| Clonal Evolution | 1 | 2021 | 16 | 0.780 |
Why?
|
| Exons | 8 | 2016 | 453 | 0.780 |
Why?
|
| Genetic Loci | 12 | 2019 | 253 | 0.780 |
Why?
|
| Body Mass Index | 9 | 2021 | 776 | 0.760 |
Why?
|
| Gene Deletion | 10 | 2002 | 341 | 0.740 |
Why?
|
| Germ Cells | 4 | 2023 | 130 | 0.740 |
Why?
|
| RNA, Long Noncoding | 2 | 2021 | 120 | 0.730 |
Why?
|
| Cross-Sectional Studies | 9 | 2023 | 1729 | 0.730 |
Why?
|
| Risk | 25 | 2022 | 657 | 0.720 |
Why?
|
| Healthcare Disparities | 7 | 2023 | 431 | 0.720 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2019 | 605 | 0.720 |
Why?
|
| Demography | 2 | 2023 | 183 | 0.710 |
Why?
|
| Genomic Instability | 5 | 2021 | 83 | 0.710 |
Why?
|
| Preventive Health Services | 2 | 2019 | 39 | 0.710 |
Why?
|
| Radiation Oncology | 2 | 2020 | 122 | 0.710 |
Why?
|
| Medicine, African Traditional | 1 | 2020 | 3 | 0.710 |
Why?
|
| Introns | 5 | 2021 | 301 | 0.700 |
Why?
|
| Health Personnel | 2 | 2022 | 214 | 0.700 |
Why?
|
| Peritoneal Neoplasms | 3 | 2019 | 181 | 0.700 |
Why?
|
| Alternative Splicing | 5 | 2016 | 212 | 0.700 |
Why?
|
| In Situ Hybridization, Fluorescence | 17 | 2022 | 352 | 0.690 |
Why?
|
| Doxorubicin | 9 | 2020 | 293 | 0.690 |
Why?
|
| Pedigree | 18 | 2018 | 971 | 0.690 |
Why?
|
| Biomedical Research | 5 | 2019 | 403 | 0.690 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 2328 | 0.680 |
Why?
|
| Pharmacogenetics | 2 | 2021 | 437 | 0.680 |
Why?
|
| Male | 71 | 2023 | 42614 | 0.670 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2020 | 233 | 0.670 |
Why?
|
| Genes, erbB-2 | 4 | 2009 | 25 | 0.660 |
Why?
|
| Bromobenzenes | 1 | 2019 | 2 | 0.660 |
Why?
|
| CpG Islands | 5 | 2016 | 158 | 0.650 |
Why?
|
| Copper-transporting ATPases | 1 | 2019 | 12 | 0.650 |
Why?
|
| Neovascularization, Pathologic | 3 | 2019 | 354 | 0.650 |
Why?
|
| Molybdenum | 1 | 2019 | 12 | 0.650 |
Why?
|
| Benzothiazoles | 1 | 2019 | 16 | 0.650 |
Why?
|
| Checkpoint Kinase 2 | 2 | 2018 | 26 | 0.650 |
Why?
|
| DNA-Binding Proteins | 13 | 2016 | 1244 | 0.650 |
Why?
|
| Clinical Trials as Topic | 6 | 2020 | 1134 | 0.650 |
Why?
|
| Young Adult | 30 | 2024 | 6389 | 0.640 |
Why?
|
| Fluorobenzenes | 1 | 2019 | 33 | 0.640 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2018 | 57 | 0.640 |
Why?
|
| Haplotypes | 15 | 2019 | 637 | 0.640 |
Why?
|
| Minority Groups | 5 | 2018 | 147 | 0.640 |
Why?
|
| Transcription Factors | 12 | 2017 | 1665 | 0.640 |
Why?
|
| beta Catenin | 4 | 2015 | 267 | 0.630 |
Why?
|
| Tumor Microenvironment | 4 | 2021 | 476 | 0.630 |
Why?
|
| Proportional Hazards Models | 21 | 2021 | 848 | 0.620 |
Why?
|
| Physicians | 4 | 2022 | 691 | 0.620 |
Why?
|
| Genetic Variation | 14 | 2021 | 1380 | 0.610 |
Why?
|
| Polymorphism, Genetic | 9 | 2012 | 825 | 0.610 |
Why?
|
| Molecular Chaperones | 1 | 2019 | 123 | 0.610 |
Why?
|
| Carcinoma | 3 | 2014 | 438 | 0.600 |
Why?
|
| Women, Working | 1 | 2017 | 7 | 0.600 |
Why?
|
| Premenopause | 6 | 2013 | 57 | 0.570 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 2 | 2018 | 10 | 0.570 |
Why?
|
| Genome, Human | 6 | 2020 | 791 | 0.570 |
Why?
|
| Medicaid | 1 | 2020 | 238 | 0.570 |
Why?
|
| Brain Neoplasms | 5 | 2016 | 783 | 0.570 |
Why?
|
| Molecular Epidemiology | 2 | 2019 | 54 | 0.570 |
Why?
|
| Circulating MicroRNA | 1 | 2016 | 13 | 0.540 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2017 | 145 | 0.540 |
Why?
|
| Odds Ratio | 21 | 2022 | 682 | 0.540 |
Why?
|
| Disease-Free Survival | 12 | 2023 | 1168 | 0.530 |
Why?
|
| Bibliometrics | 1 | 2016 | 37 | 0.520 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 3 | 2019 | 6 | 0.520 |
Why?
|
| Chromosome Mapping | 19 | 2019 | 1074 | 0.520 |
Why?
|
| Genetic Association Studies | 12 | 2019 | 294 | 0.520 |
Why?
|
| Survival Analysis | 19 | 2021 | 1497 | 0.520 |
Why?
|
| Socioeconomic Factors | 7 | 2020 | 594 | 0.520 |
Why?
|
| Microsatellite Repeats | 4 | 2016 | 148 | 0.520 |
Why?
|
| Adenocarcinoma | 6 | 2011 | 1183 | 0.510 |
Why?
|
| Body Weight | 3 | 2021 | 453 | 0.510 |
Why?
|
| Purine-Nucleoside Phosphorylase | 11 | 2001 | 20 | 0.510 |
Why?
|
| Biological Products | 1 | 2018 | 158 | 0.510 |
Why?
|
| Estrogen Receptor beta | 2 | 2012 | 25 | 0.510 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 10 | 2018 | 105 | 0.500 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2017 | 75 | 0.500 |
Why?
|
| Uganda | 5 | 2024 | 38 | 0.500 |
Why?
|
| Retrospective Studies | 28 | 2023 | 9185 | 0.480 |
Why?
|
| Genes, Tumor Suppressor | 13 | 2016 | 153 | 0.480 |
Why?
|
| Genetic Carrier Screening | 8 | 2016 | 60 | 0.480 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 79 | 0.480 |
Why?
|
| Chromosomes, Human, Pair 5 | 4 | 2008 | 109 | 0.480 |
Why?
|
| MicroRNAs | 6 | 2019 | 556 | 0.470 |
Why?
|
| Transcriptome | 5 | 2023 | 661 | 0.460 |
Why?
|
| ErbB Receptors | 5 | 2012 | 498 | 0.450 |
Why?
|
| Nuclear Proteins | 6 | 2017 | 727 | 0.450 |
Why?
|
| Breast Diseases | 4 | 2024 | 100 | 0.440 |
Why?
|
| Quinazolines | 5 | 2015 | 212 | 0.440 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 405 | 0.440 |
Why?
|
| Pathology | 1 | 2013 | 32 | 0.440 |
Why?
|
| Computer-Assisted Instruction | 1 | 2013 | 44 | 0.430 |
Why?
|
| Leukemia | 3 | 2014 | 322 | 0.430 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2013 | 21 | 0.430 |
Why?
|
| Base Sequence | 19 | 2016 | 2329 | 0.430 |
Why?
|
| Age Factors | 19 | 2019 | 1880 | 0.430 |
Why?
|
| Chromosome Disorders | 4 | 2001 | 113 | 0.420 |
Why?
|
| Postmenopause | 3 | 2013 | 102 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 6 | 5 | 2019 | 125 | 0.420 |
Why?
|
| Gene Rearrangement | 6 | 2010 | 177 | 0.420 |
Why?
|
| Reproductive Physiological Phenomena | 1 | 2012 | 4 | 0.420 |
Why?
|
| Africa South of the Sahara | 4 | 2023 | 23 | 0.420 |
Why?
|
| Logistic Models | 12 | 2017 | 1214 | 0.410 |
Why?
|
| Global Health | 3 | 2015 | 193 | 0.410 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2012 | 48 | 0.410 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2011 | 665 | 0.410 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 3 | 2019 | 14 | 0.410 |
Why?
|
| Genes, myc | 2 | 2011 | 40 | 0.410 |
Why?
|
| Macrophages | 2 | 2013 | 581 | 0.410 |
Why?
|
| Epigenomics | 1 | 2013 | 103 | 0.410 |
Why?
|
| DNA, Neoplasm | 7 | 2019 | 266 | 0.410 |
Why?
|
| MCF-7 Cells | 7 | 2018 | 114 | 0.400 |
Why?
|
| Awareness | 1 | 2013 | 88 | 0.400 |
Why?
|
| Lactation | 1 | 2012 | 54 | 0.400 |
Why?
|
| Deoxycytidine | 1 | 2013 | 211 | 0.400 |
Why?
|
| RNA, Messenger | 11 | 2022 | 2025 | 0.400 |
Why?
|
| Waist-Hip Ratio | 1 | 2012 | 20 | 0.400 |
Why?
|
| Body Fat Distribution | 1 | 2012 | 13 | 0.400 |
Why?
|
| Adolescent | 27 | 2023 | 9327 | 0.400 |
Why?
|
| Delivery of Health Care | 2 | 2015 | 436 | 0.400 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 217 | 0.390 |
Why?
|
| Fluorouracil | 2 | 2013 | 549 | 0.390 |
Why?
|
| Surveys and Questionnaires | 9 | 2020 | 2649 | 0.390 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 111 | 0.390 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 119 | 0.390 |
Why?
|
| E-Box Elements | 1 | 2011 | 5 | 0.380 |
Why?
|
| Estrogen Antagonists | 2 | 2011 | 48 | 0.380 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 5 | 2012 | 474 | 0.380 |
Why?
|
| Cooking | 3 | 2017 | 56 | 0.380 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 2019 | 108 | 0.380 |
Why?
|
| Head and Neck Neoplasms | 6 | 2019 | 1061 | 0.370 |
Why?
|
| Biopsy | 7 | 2021 | 1184 | 0.370 |
Why?
|
| Tumor Cells, Cultured | 21 | 2006 | 1048 | 0.370 |
Why?
|
| Survival Rate | 11 | 2023 | 1898 | 0.370 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2011 | 52 | 0.360 |
Why?
|
| ras Proteins | 1 | 2011 | 130 | 0.360 |
Why?
|
| Prostatic Neoplasms | 8 | 2019 | 1735 | 0.360 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2011 | 147 | 0.360 |
Why?
|
| Fallopian Tubes | 3 | 2017 | 42 | 0.360 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 4 | 2015 | 47 | 0.350 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2001 | 366 | 0.350 |
Why?
|
| Chicago | 11 | 2021 | 1431 | 0.350 |
Why?
|
| Interdisciplinary Communication | 2 | 2012 | 131 | 0.350 |
Why?
|
| Gene Fusion | 1 | 2010 | 42 | 0.350 |
Why?
|
| Gene Frequency | 11 | 2016 | 687 | 0.350 |
Why?
|
| Group Processes | 1 | 2010 | 31 | 0.350 |
Why?
|
| Community-Institutional Relations | 1 | 2010 | 29 | 0.350 |
Why?
|
| Age of Onset | 13 | 2018 | 319 | 0.350 |
Why?
|
| Quantitative Trait Loci | 8 | 2023 | 614 | 0.350 |
Why?
|
| Lung Neoplasms | 10 | 2023 | 2368 | 0.340 |
Why?
|
| Homozygote | 7 | 2007 | 201 | 0.340 |
Why?
|
| Contrast Media | 8 | 2020 | 1084 | 0.340 |
Why?
|
| Molecular Sequence Data | 16 | 2012 | 3024 | 0.340 |
Why?
|
| Cell Proliferation | 9 | 2019 | 1669 | 0.340 |
Why?
|
| Prospective Studies | 16 | 2022 | 4322 | 0.340 |
Why?
|
| Sequence Deletion | 7 | 2019 | 205 | 0.330 |
Why?
|
| Leukemia, Myeloid | 3 | 2004 | 249 | 0.330 |
Why?
|
| Quality Improvement | 1 | 2013 | 457 | 0.330 |
Why?
|
| DNA Copy Number Variations | 4 | 2022 | 182 | 0.330 |
Why?
|
| Family | 7 | 2018 | 325 | 0.330 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 1998 | 261 | 0.330 |
Why?
|
| Endometrial Neoplasms | 3 | 2022 | 208 | 0.330 |
Why?
|
| Mice | 19 | 2023 | 11846 | 0.320 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2019 | 44 | 0.320 |
Why?
|
| Risk Reduction Behavior | 5 | 2014 | 97 | 0.320 |
Why?
|
| Truth Disclosure | 3 | 2018 | 93 | 0.320 |
Why?
|
| Colonic Neoplasms | 3 | 2016 | 571 | 0.320 |
Why?
|
| Complementary Therapies | 2 | 2023 | 56 | 0.320 |
Why?
|
| Trans-Activators | 5 | 2021 | 443 | 0.320 |
Why?
|
| Information Storage and Retrieval | 2 | 2008 | 121 | 0.310 |
Why?
|
| Linkage Disequilibrium | 9 | 2021 | 477 | 0.310 |
Why?
|
| Carrier Proteins | 7 | 2016 | 678 | 0.310 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2013 | 952 | 0.310 |
Why?
|
| Systems Integration | 1 | 2008 | 36 | 0.310 |
Why?
|
| Database Management Systems | 1 | 2008 | 41 | 0.310 |
Why?
|
| Universities | 3 | 2019 | 145 | 0.300 |
Why?
|
| DNA Repair | 6 | 2014 | 363 | 0.300 |
Why?
|
| Aneuploidy | 2 | 2005 | 57 | 0.300 |
Why?
|
| Disclosure | 4 | 2020 | 109 | 0.300 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2021 | 1255 | 0.300 |
Why?
|
| Immunohistochemistry | 12 | 2022 | 1799 | 0.290 |
Why?
|
| Cell Cycle Proteins | 5 | 2016 | 399 | 0.290 |
Why?
|
| Allelic Imbalance | 3 | 2013 | 22 | 0.290 |
Why?
|
| Gene Expression | 7 | 2018 | 1309 | 0.290 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2020 | 67 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2021 | 484 | 0.280 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 188 | 0.280 |
Why?
|
| Bilirubin | 1 | 2007 | 131 | 0.280 |
Why?
|
| Cameroon | 4 | 2024 | 16 | 0.280 |
Why?
|
| Multigene Family | 6 | 2014 | 202 | 0.280 |
Why?
|
| Capecitabine | 2 | 2020 | 93 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2000 | 79 | 0.280 |
Why?
|
| Computational Biology | 3 | 2016 | 551 | 0.270 |
Why?
|
| Social Environment | 1 | 2008 | 187 | 0.270 |
Why?
|
| Binding Sites | 7 | 2020 | 1121 | 0.270 |
Why?
|
| Neoplasm Grading | 4 | 2021 | 374 | 0.270 |
Why?
|
| Signal Transduction | 9 | 2018 | 3403 | 0.270 |
Why?
|
| Schools, Medical | 2 | 2019 | 136 | 0.270 |
Why?
|
| Genetics, Population | 4 | 2018 | 407 | 0.270 |
Why?
|
| Obesity | 3 | 2013 | 972 | 0.260 |
Why?
|
| Hospitals, Teaching | 2 | 2018 | 118 | 0.260 |
Why?
|
| Cell Cycle | 2 | 2020 | 508 | 0.260 |
Why?
|
| Quality of Health Care | 3 | 2017 | 387 | 0.260 |
Why?
|
| Pregnancy | 10 | 2018 | 3040 | 0.260 |
Why?
|
| Prevalence | 7 | 2021 | 1250 | 0.260 |
Why?
|
| Interviews as Topic | 4 | 2018 | 344 | 0.260 |
Why?
|
| Menarche | 2 | 2021 | 30 | 0.260 |
Why?
|
| Phenotype | 10 | 2019 | 2450 | 0.250 |
Why?
|
| Multivariate Analysis | 10 | 2017 | 983 | 0.250 |
Why?
|
| Developing Countries | 2 | 2016 | 80 | 0.250 |
Why?
|
| Brazil | 2 | 2022 | 75 | 0.250 |
Why?
|
| Depressive Disorder | 1 | 2006 | 221 | 0.250 |
Why?
|
| Glioma | 5 | 1998 | 294 | 0.250 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2023 | 25 | 0.250 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2019 | 490 | 0.240 |
Why?
|
| Polymerase Chain Reaction | 10 | 2011 | 919 | 0.240 |
Why?
|
| Community Participation | 2 | 2014 | 38 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2023 | 854 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2015 | 1096 | 0.240 |
Why?
|
| Apoptosis | 4 | 2019 | 1717 | 0.240 |
Why?
|
| Air Pollution, Indoor | 2 | 2017 | 64 | 0.240 |
Why?
|
| Family Health | 5 | 2011 | 162 | 0.240 |
Why?
|
| RNA, Small Interfering | 4 | 2015 | 557 | 0.230 |
Why?
|
| Multifactorial Inheritance | 4 | 2022 | 173 | 0.230 |
Why?
|
| Weight Gain | 2 | 2021 | 119 | 0.230 |
Why?
|
| Data Collection | 3 | 2023 | 377 | 0.230 |
Why?
|
| Salpingostomy | 1 | 2004 | 1 | 0.230 |
Why?
|
| Pseudogenes | 3 | 2021 | 34 | 0.230 |
Why?
|
| Vulnerable Populations | 2 | 2020 | 84 | 0.230 |
Why?
|
| Population Surveillance | 4 | 2019 | 216 | 0.230 |
Why?
|
| Genetic Heterogeneity | 2 | 2021 | 67 | 0.230 |
Why?
|
| Rosaniline Dyes | 1 | 2023 | 9 | 0.230 |
Why?
|
| Databases, Genetic | 4 | 2019 | 269 | 0.230 |
Why?
|
| Sequence Analysis, DNA | 7 | 2018 | 869 | 0.220 |
Why?
|
| Copper | 2 | 2019 | 78 | 0.220 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 103 | 0.220 |
Why?
|
| Animals | 20 | 2023 | 27516 | 0.220 |
Why?
|
| GATA3 Transcription Factor | 2 | 2021 | 48 | 0.220 |
Why?
|
| Metformin | 2 | 2016 | 124 | 0.220 |
Why?
|
| Marital Status | 1 | 2023 | 42 | 0.220 |
Why?
|
| Marketing of Health Services | 1 | 2003 | 15 | 0.220 |
Why?
|
| Cyclophosphamide | 4 | 2020 | 301 | 0.220 |
Why?
|
| DNA Mismatch Repair | 2 | 2015 | 58 | 0.220 |
Why?
|
| Carcinoma, Lobular | 3 | 2014 | 81 | 0.220 |
Why?
|
| Epithelial-Mesenchymal Transition | 5 | 2014 | 98 | 0.220 |
Why?
|
| Neoplasm, Residual | 2 | 2023 | 181 | 0.220 |
Why?
|
| Yoga | 1 | 2023 | 5 | 0.210 |
Why?
|
| Meditation | 1 | 2023 | 5 | 0.210 |
Why?
|
| Loss of Heterozygosity | 5 | 2016 | 86 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2013 | 885 | 0.210 |
Why?
|
| Age Distribution | 4 | 2013 | 199 | 0.210 |
Why?
|
| Hypoglycemic Agents | 2 | 2016 | 351 | 0.210 |
Why?
|
| Metabolome | 1 | 2023 | 51 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2023 | 476 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2015 | 165 | 0.200 |
Why?
|
| Hematologic Neoplasms | 1 | 2006 | 344 | 0.200 |
Why?
|
| Interferons | 6 | 1995 | 127 | 0.200 |
Why?
|
| Disease Progression | 8 | 2019 | 1469 | 0.200 |
Why?
|
| Pharmacists | 1 | 2022 | 33 | 0.200 |
Why?
|
| Physician's Role | 2 | 2017 | 176 | 0.200 |
Why?
|
| Synaptophysin | 1 | 2021 | 11 | 0.200 |
Why?
|
| Mutation, Missense | 2 | 2007 | 280 | 0.200 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 2017 | 154 | 0.200 |
Why?
|
| Social Class | 2 | 2016 | 137 | 0.190 |
Why?
|
| Exome | 2 | 2019 | 131 | 0.190 |
Why?
|
| DNA Probes | 5 | 1997 | 77 | 0.190 |
Why?
|
| Public Health | 2 | 2013 | 140 | 0.190 |
Why?
|
| Genes, p16 | 1 | 2001 | 8 | 0.190 |
Why?
|
| DNA Helicases | 1 | 2022 | 84 | 0.190 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 3670 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 8 | 2009 | 693 | 0.190 |
Why?
|
| Internationality | 2 | 2019 | 69 | 0.190 |
Why?
|
| Microfilament Proteins | 2 | 2013 | 212 | 0.190 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2001 | 11 | 0.190 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2013 | 306 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2019 | 274 | 0.190 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2010 | 12 | 0.180 |
Why?
|
| Needs Assessment | 1 | 2022 | 161 | 0.180 |
Why?
|
| Women's Health | 2 | 2018 | 103 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2012 | 359 | 0.180 |
Why?
|
| Parent-Child Relations | 3 | 2012 | 79 | 0.180 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 51 | 0.180 |
Why?
|
| Fourier Analysis | 4 | 2014 | 128 | 0.180 |
Why?
|
| Specimen Handling | 1 | 2021 | 103 | 0.180 |
Why?
|
| Chromosomes, Artificial, Yeast | 5 | 1995 | 36 | 0.180 |
Why?
|
| Small Molecule Libraries | 2 | 2019 | 65 | 0.180 |
Why?
|
| Tumor Escape | 1 | 2021 | 51 | 0.180 |
Why?
|
| Africa | 4 | 2021 | 101 | 0.180 |
Why?
|
| Withholding Treatment | 1 | 2021 | 116 | 0.180 |
Why?
|
| Microarray Analysis | 2 | 2018 | 95 | 0.180 |
Why?
|
| Databases, Factual | 6 | 2017 | 864 | 0.180 |
Why?
|
| Telemedicine | 1 | 2023 | 192 | 0.180 |
Why?
|
| RNA-Binding Proteins | 1 | 2003 | 279 | 0.180 |
Why?
|
| Pregnancy Complications | 2 | 2018 | 345 | 0.180 |
Why?
|
| Models, Organizational | 1 | 2020 | 48 | 0.180 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 166 | 0.180 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 125 | 0.180 |
Why?
|
| Neoplasm Metastasis | 4 | 2013 | 1066 | 0.180 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2020 | 42 | 0.180 |
Why?
|
| Echo-Planar Imaging | 4 | 2017 | 52 | 0.180 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2018 | 48 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 5 | 2015 | 569 | 0.170 |
Why?
|
| Water | 3 | 2012 | 285 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2019 | 65 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2000 | 194 | 0.170 |
Why?
|
| Gain of Function Mutation | 1 | 2019 | 13 | 0.170 |
Why?
|
| Karyotyping | 7 | 2000 | 253 | 0.170 |
Why?
|
| Image Enhancement | 4 | 2020 | 565 | 0.170 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2019 | 25 | 0.170 |
Why?
|
| Survivorship | 1 | 2020 | 20 | 0.170 |
Why?
|
| Trastuzumab | 3 | 2020 | 73 | 0.170 |
Why?
|
| Gene Amplification | 5 | 2008 | 135 | 0.170 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2019 | 4 | 0.170 |
Why?
|
| Liver | 4 | 2013 | 1211 | 0.170 |
Why?
|
| Health Occupations | 1 | 2019 | 6 | 0.170 |
Why?
|
| Research Design | 5 | 2019 | 591 | 0.170 |
Why?
|
| Nucleotidyltransferases | 1 | 2019 | 31 | 0.170 |
Why?
|
| Noncommunicable Diseases | 1 | 2019 | 6 | 0.170 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2019 | 12 | 0.170 |
Why?
|
| Patient Care Planning | 1 | 2020 | 83 | 0.170 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2016 | 198 | 0.170 |
Why?
|
| Population Groups | 1 | 2019 | 41 | 0.170 |
Why?
|
| Treatment Outcome | 10 | 2020 | 8264 | 0.160 |
Why?
|
| Interferon Type I | 2 | 1998 | 186 | 0.160 |
Why?
|
| Radiographic Image Enhancement | 2 | 2012 | 465 | 0.160 |
Why?
|
| Hospitals, University | 1 | 2020 | 196 | 0.160 |
Why?
|
| Algorithms | 8 | 2017 | 1908 | 0.160 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 37 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 16 | 5 | 2013 | 79 | 0.160 |
Why?
|
| Pneumonia | 1 | 2001 | 183 | 0.160 |
Why?
|
| Exercise | 2 | 2023 | 327 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 2 | 2018 | 162 | 0.160 |
Why?
|
| High Mobility Group Proteins | 2 | 2016 | 27 | 0.160 |
Why?
|
| Interdisciplinary Studies | 1 | 2019 | 20 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 112 | 0.160 |
Why?
|
| DNA Replication | 1 | 2019 | 171 | 0.160 |
Why?
|
| Pandemics | 2 | 2023 | 778 | 0.160 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 19 | 0.160 |
Why?
|
| Health Behavior | 3 | 2010 | 185 | 0.160 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2013 | 45 | 0.160 |
Why?
|
| Cell Survival | 3 | 2019 | 983 | 0.160 |
Why?
|
| Sulfonamides | 2 | 2019 | 319 | 0.160 |
Why?
|
| Inheritance Patterns | 1 | 2019 | 48 | 0.160 |
Why?
|
| Research Personnel | 1 | 2019 | 72 | 0.160 |
Why?
|
| Protein Binding | 4 | 2016 | 1491 | 0.160 |
Why?
|
| RNA Interference | 4 | 2015 | 376 | 0.160 |
Why?
|
| Gene Dosage | 5 | 2011 | 210 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2014 | 137 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 124 | 0.150 |
Why?
|
| Homologous Recombination | 1 | 2018 | 53 | 0.150 |
Why?
|
| Azacitidine | 3 | 2009 | 147 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2017 | 691 | 0.150 |
Why?
|
| Longitudinal Studies | 5 | 2023 | 1083 | 0.150 |
Why?
|
| Oxidative Stress | 2 | 2019 | 458 | 0.150 |
Why?
|
| Europe | 5 | 2021 | 324 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2020 | 95 | 0.150 |
Why?
|
| Time Factors | 12 | 2015 | 5357 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 172 | 0.150 |
Why?
|
| Occupations | 1 | 2017 | 25 | 0.150 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 88 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 201 | 0.150 |
Why?
|
| Cell Line | 7 | 2016 | 2495 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 290 | 0.150 |
Why?
|
| Haptoglobins | 1 | 2017 | 9 | 0.150 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2012 | 39 | 0.150 |
Why?
|
| Cell Movement | 2 | 2019 | 786 | 0.150 |
Why?
|
| Patient Preference | 1 | 2018 | 111 | 0.150 |
Why?
|
| Combined Modality Therapy | 5 | 2023 | 1704 | 0.150 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2017 | 9 | 0.150 |
Why?
|
| Human Genome Project | 1 | 1997 | 19 | 0.150 |
Why?
|
| Genetic Markers | 5 | 2008 | 476 | 0.150 |
Why?
|
| Hydroxamic Acids | 2 | 2009 | 50 | 0.150 |
Why?
|
| Asthma | 2 | 2019 | 983 | 0.140 |
Why?
|
| 3' Untranslated Regions | 3 | 2019 | 95 | 0.140 |
Why?
|
| Ovary | 1 | 2019 | 262 | 0.140 |
Why?
|
| Lymphatic Metastasis | 6 | 2018 | 495 | 0.140 |
Why?
|
| Barbados | 2 | 2018 | 7 | 0.140 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 27 | 0.140 |
Why?
|
| Carboplatin | 2 | 2016 | 312 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 177 | 0.140 |
Why?
|
| DNA Glycosylases | 2 | 2014 | 25 | 0.140 |
Why?
|
| Communication | 2 | 2018 | 461 | 0.140 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2017 | 64 | 0.140 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2016 | 51 | 0.140 |
Why?
|
| Maternal Exposure | 1 | 2017 | 58 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 1995 | 399 | 0.140 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2014 | 32 | 0.140 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 1996 | 6 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 241 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 54 | 0.140 |
Why?
|
| Placenta Growth Factor | 1 | 2017 | 70 | 0.140 |
Why?
|
| Body Weights and Measures | 2 | 2021 | 27 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1054 | 0.140 |
Why?
|
| Human Migration | 1 | 2016 | 26 | 0.140 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1998 | 153 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 210 | 0.140 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 118 | 0.140 |
Why?
|
| Ribonuclease III | 1 | 2016 | 16 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2016 | 59 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2017 | 102 | 0.130 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 559 | 0.130 |
Why?
|
| Decanoic Acids | 1 | 2016 | 11 | 0.130 |
Why?
|
| Interleukin-11 | 2 | 2013 | 20 | 0.130 |
Why?
|
| Glycolysis | 1 | 2017 | 135 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2017 | 94 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 146 | 0.130 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2019 | 182 | 0.130 |
Why?
|
| Vidarabine | 1 | 1996 | 144 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 1998 | 449 | 0.130 |
Why?
|
| Placenta | 1 | 2017 | 181 | 0.130 |
Why?
|
| Leuprolide | 1 | 2016 | 35 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2008 | 1130 | 0.130 |
Why?
|
| Carmustine | 1 | 2016 | 70 | 0.130 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2015 | 14 | 0.130 |
Why?
|
| Internal-External Control | 1 | 2016 | 45 | 0.130 |
Why?
|
| Codon, Terminator | 1 | 2015 | 22 | 0.130 |
Why?
|
| Information Management | 1 | 2015 | 7 | 0.130 |
Why?
|
| Polyesters | 1 | 2016 | 42 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2015 | 313 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 141 | 0.130 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 21 | 0.130 |
Why?
|
| Gene Flow | 1 | 2016 | 93 | 0.130 |
Why?
|
| Cloning, Molecular | 3 | 1995 | 645 | 0.130 |
Why?
|
| Epithelial Cells | 3 | 2017 | 689 | 0.130 |
Why?
|
| Cell Nucleus | 2 | 2021 | 602 | 0.130 |
Why?
|
| Air Pollution | 1 | 2017 | 93 | 0.130 |
Why?
|
| Quality of Life | 2 | 2021 | 1680 | 0.130 |
Why?
|
| Internal Medicine | 2 | 2009 | 362 | 0.130 |
Why?
|
| Religion | 1 | 2016 | 88 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2016 | 107 | 0.130 |
Why?
|
| Incidence | 8 | 2015 | 1600 | 0.130 |
Why?
|
| Genes, Mitochondrial | 1 | 2015 | 10 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2017 | 234 | 0.130 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 61 | 0.130 |
Why?
|
| Craniotomy | 1 | 2016 | 89 | 0.130 |
Why?
|
| Nitriles | 1 | 2016 | 156 | 0.130 |
Why?
|
| Transcription, Genetic | 3 | 2009 | 1158 | 0.120 |
Why?
|
| Health Services Needs and Demand | 2 | 2013 | 108 | 0.120 |
Why?
|
| Triazoles | 1 | 2016 | 104 | 0.120 |
Why?
|
| Lymph Nodes | 2 | 2009 | 550 | 0.120 |
Why?
|
| Sensitivity and Specificity | 8 | 2014 | 2018 | 0.120 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2015 | 13 | 0.120 |
Why?
|
| Vitamin D | 1 | 2017 | 269 | 0.120 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2013 | 33 | 0.120 |
Why?
|
| Health Surveys | 2 | 2021 | 240 | 0.120 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1995 | 43 | 0.120 |
Why?
|
| Telephone | 3 | 2020 | 36 | 0.120 |
Why?
|
| Vimentin | 2 | 2012 | 46 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 303 | 0.120 |
Why?
|
| Pilot Projects | 5 | 2022 | 871 | 0.120 |
Why?
|
| Wnt Proteins | 2 | 2018 | 130 | 0.120 |
Why?
|
| Terminology as Topic | 2 | 2015 | 222 | 0.120 |
Why?
|
| Cadherins | 2 | 2018 | 163 | 0.120 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2012 | 55 | 0.120 |
Why?
|
| Bone Marrow | 2 | 1995 | 443 | 0.120 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2016 | 284 | 0.120 |
Why?
|
| Chromosome Banding | 3 | 2004 | 73 | 0.120 |
Why?
|
| Interprofessional Relations | 2 | 2019 | 121 | 0.120 |
Why?
|
| Health Literacy | 1 | 2016 | 73 | 0.120 |
Why?
|
| Genes, Reporter | 2 | 2015 | 274 | 0.120 |
Why?
|
| Social Isolation | 2 | 2021 | 67 | 0.120 |
Why?
|
| Cytoskeleton | 2 | 2013 | 195 | 0.120 |
Why?
|
| Mammary Glands, Human | 1 | 2014 | 24 | 0.120 |
Why?
|
| Laboratories | 2 | 2013 | 44 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2004 | 798 | 0.120 |
Why?
|
| ROC Curve | 7 | 2012 | 778 | 0.120 |
Why?
|
| Registries | 6 | 2021 | 803 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 103 | 0.120 |
Why?
|
| Biomarkers | 4 | 2017 | 1774 | 0.120 |
Why?
|
| Curriculum | 1 | 2019 | 572 | 0.110 |
Why?
|
| Health Care Reform | 1 | 2015 | 85 | 0.110 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 2013 | 8 | 0.110 |
Why?
|
| Oncogenes | 1 | 2014 | 97 | 0.110 |
Why?
|
| Primary Prevention | 2 | 2014 | 82 | 0.110 |
Why?
|
| Predictive Value of Tests | 7 | 2020 | 1729 | 0.110 |
Why?
|
| Students, Medical | 1 | 2019 | 425 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 28 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 2 | 2010 | 511 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 306 | 0.110 |
Why?
|
| Phytotherapy | 1 | 2014 | 136 | 0.110 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 126 | 0.110 |
Why?
|
| Epidemiologic Studies | 1 | 2013 | 16 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 607 | 0.110 |
Why?
|
| Breast Self-Examination | 1 | 2013 | 3 | 0.110 |
Why?
|
| Computer Simulation | 4 | 2018 | 1101 | 0.110 |
Why?
|
| Communications Media | 1 | 2013 | 2 | 0.110 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2013 | 17 | 0.110 |
Why?
|
| Smoke | 1 | 2013 | 27 | 0.110 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 865 | 0.110 |
Why?
|
| Rescue Work | 1 | 2012 | 7 | 0.110 |
Why?
|
| Inhalation Exposure | 1 | 2013 | 31 | 0.110 |
Why?
|
| Relief Work | 1 | 2012 | 7 | 0.110 |
Why?
|
| Feasibility Studies | 2 | 2013 | 785 | 0.110 |
Why?
|
| Informed Consent | 2 | 2014 | 275 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2014 | 306 | 0.100 |
Why?
|
| Epithelium | 2 | 2013 | 323 | 0.100 |
Why?
|
| Earthquakes | 1 | 2012 | 13 | 0.100 |
Why?
|
| Mass Casualty Incidents | 1 | 2012 | 13 | 0.100 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1992 | 30 | 0.100 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2006 | 418 | 0.100 |
Why?
|
| Cooperative Behavior | 2 | 2012 | 179 | 0.100 |
Why?
|
| Altruism | 1 | 2012 | 34 | 0.100 |
Why?
|
| Disasters | 1 | 2012 | 22 | 0.100 |
Why?
|
| Tanzania | 1 | 2012 | 47 | 0.100 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 99 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 314 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 1993 | 133 | 0.100 |
Why?
|
| Drug Discovery | 2 | 2015 | 107 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 52 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2016 | 287 | 0.100 |
Why?
|
| Hypoxia | 1 | 2017 | 657 | 0.100 |
Why?
|
| Cytoplasm | 1 | 2013 | 285 | 0.100 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2010 | 137 | 0.100 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2018 | 64 | 0.100 |
Why?
|
| Waist Circumference | 1 | 2012 | 22 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2011 | 586 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 260 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 225 | 0.100 |
Why?
|
| Cancer Care Facilities | 2 | 2015 | 30 | 0.100 |
Why?
|
| Kisspeptins | 1 | 2011 | 4 | 0.100 |
Why?
|
| DNA, Complementary | 3 | 2007 | 391 | 0.100 |
Why?
|
| Observer Variation | 1 | 2013 | 614 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 1929 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2014 | 493 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 273 | 0.100 |
Why?
|
| Mutation Rate | 1 | 2012 | 49 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 94 | 0.100 |
Why?
|
| Polychondritis, Relapsing | 1 | 2011 | 5 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 245 | 0.100 |
Why?
|
| Mastectomy, Segmental | 2 | 2017 | 101 | 0.100 |
Why?
|
| Microsatellite Instability | 1 | 2011 | 53 | 0.100 |
Why?
|
| DNA, Recombinant | 1 | 2011 | 67 | 0.100 |
Why?
|
| Consensus Sequence | 1 | 2011 | 66 | 0.100 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 44 | 0.100 |
Why?
|
| Lymphocytes | 4 | 2005 | 468 | 0.100 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2011 | 5 | 0.090 |
Why?
|
| Bayes Theorem | 3 | 2022 | 381 | 0.090 |
Why?
|
| Telomerase | 1 | 2011 | 67 | 0.090 |
Why?
|
| Deafness | 1 | 2011 | 48 | 0.090 |
Why?
|
| Pericardial Effusion | 1 | 1991 | 20 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 425 | 0.090 |
Why?
|
| Health Promotion | 1 | 2013 | 165 | 0.090 |
Why?
|
| Internet | 1 | 2013 | 323 | 0.090 |
Why?
|
| Stomach Neoplasms | 2 | 2011 | 288 | 0.090 |
Why?
|
| Pleural Effusion | 1 | 1991 | 47 | 0.090 |
Why?
|
| Contraceptives, Oral | 2 | 2020 | 46 | 0.090 |
Why?
|
| Arthritis | 1 | 2011 | 48 | 0.090 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2011 | 46 | 0.090 |
Why?
|
| Radiotherapy | 2 | 2011 | 332 | 0.090 |
Why?
|
| Mice, Nude | 4 | 2019 | 816 | 0.090 |
Why?
|
| Parents | 2 | 2012 | 289 | 0.090 |
Why?
|
| Ataxin-7 | 1 | 2010 | 5 | 0.090 |
Why?
|
| Poverty | 2 | 2013 | 183 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2013 | 275 | 0.090 |
Why?
|
| Serine Endopeptidases | 1 | 2011 | 146 | 0.090 |
Why?
|
| Chromosome Breakpoints | 1 | 2010 | 15 | 0.090 |
Why?
|
| Heredity | 1 | 2010 | 19 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2012 | 171 | 0.090 |
Why?
|
| Protein Isoforms | 1 | 2011 | 276 | 0.090 |
Why?
|
| Minors | 1 | 2010 | 15 | 0.090 |
Why?
|
| Rad51 Recombinase | 2 | 2009 | 81 | 0.090 |
Why?
|
| Histones | 2 | 2013 | 333 | 0.090 |
Why?
|
| Interinstitutional Relations | 1 | 2010 | 29 | 0.090 |
Why?
|
| HIV Infections | 1 | 2019 | 847 | 0.090 |
Why?
|
| Repressor Proteins | 2 | 2011 | 423 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 2011 | 181 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 160 | 0.090 |
Why?
|
| Blotting, Southern | 3 | 1995 | 127 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 384 | 0.090 |
Why?
|
| Taxoids | 3 | 2020 | 124 | 0.090 |
Why?
|
| Models, Genetic | 4 | 2018 | 948 | 0.090 |
Why?
|
| SEER Program | 2 | 2014 | 205 | 0.090 |
Why?
|
| Senegal | 1 | 2009 | 4 | 0.090 |
Why?
|
| Hypersensitivity | 1 | 2011 | 159 | 0.080 |
Why?
|
| Restriction Mapping | 3 | 1995 | 154 | 0.080 |
Why?
|
| Fatal Outcome | 3 | 2001 | 296 | 0.080 |
Why?
|
| Aromatase Inhibitors | 1 | 2009 | 29 | 0.080 |
Why?
|
| Amino Acid Sequence | 3 | 2006 | 2063 | 0.080 |
Why?
|
| RNA Splice Sites | 2 | 2016 | 58 | 0.080 |
Why?
|
| Health Services Research | 1 | 2010 | 138 | 0.080 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 244 | 0.080 |
Why?
|
| Transfection | 1 | 2011 | 909 | 0.080 |
Why?
|
| Adult Children | 1 | 2009 | 12 | 0.080 |
Why?
|
| Genes, p53 | 2 | 2001 | 109 | 0.080 |
Why?
|
| Somatomedins | 1 | 2009 | 28 | 0.080 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2009 | 60 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 22 | 0.080 |
Why?
|
| Cluster Analysis | 4 | 2013 | 371 | 0.080 |
Why?
|
| Models, Statistical | 2 | 2018 | 576 | 0.080 |
Why?
|
| Acute Disease | 3 | 2004 | 846 | 0.080 |
Why?
|
| Online Systems | 1 | 2008 | 24 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2011 | 330 | 0.080 |
Why?
|
| Skin | 1 | 2012 | 589 | 0.080 |
Why?
|
| Urban Health | 2 | 2011 | 56 | 0.080 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2008 | 10 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 5 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Recurrence | 4 | 2018 | 1144 | 0.080 |
Why?
|
| Confidence Intervals | 3 | 2013 | 221 | 0.080 |
Why?
|
| International Classification of Diseases | 1 | 2008 | 69 | 0.080 |
Why?
|
| DNA Repair Enzymes | 3 | 2015 | 55 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2019 | 84 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 2 | 2000 | 73 | 0.070 |
Why?
|
| Pyrazines | 2 | 2000 | 91 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 744 | 0.070 |
Why?
|
| Lysine | 2 | 2020 | 150 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2008 | 103 | 0.070 |
Why?
|
| Phantoms, Imaging | 1 | 2010 | 462 | 0.070 |
Why?
|
| Dinucleotide Repeats | 1 | 2007 | 14 | 0.070 |
Why?
|
| Medically Uninsured | 1 | 2007 | 60 | 0.070 |
Why?
|
| Probability | 2 | 2005 | 350 | 0.070 |
Why?
|
| Child | 8 | 2013 | 7233 | 0.070 |
Why?
|
| User-Computer Interface | 1 | 2008 | 187 | 0.070 |
Why?
|
| Hot Temperature | 2 | 2005 | 207 | 0.070 |
Why?
|
| Inflammation | 1 | 2013 | 981 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 2 | 3 | 2016 | 85 | 0.070 |
Why?
|
| Estrogens | 1 | 2008 | 200 | 0.070 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2008 | 135 | 0.070 |
Why?
|
| Methylation | 2 | 2013 | 269 | 0.070 |
Why?
|
| Datasets as Topic | 2 | 2019 | 75 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1221 | 0.070 |
Why?
|
| Urban Population | 2 | 2020 | 225 | 0.070 |
Why?
|
| Geography | 2 | 2018 | 227 | 0.070 |
Why?
|
| Research Support as Topic | 2 | 2019 | 85 | 0.070 |
Why?
|
| Chromatin | 3 | 2013 | 403 | 0.070 |
Why?
|
| Genes, APC | 1 | 2006 | 27 | 0.070 |
Why?
|
| Abortion, Therapeutic | 1 | 2006 | 11 | 0.070 |
Why?
|
| Genes, Neoplasm | 1 | 2006 | 38 | 0.070 |
Why?
|
| Subtraction Technique | 1 | 2006 | 130 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2007 | 143 | 0.070 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2006 | 49 | 0.060 |
Why?
|
| Carcinogenesis | 2 | 2018 | 213 | 0.060 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2007 | 127 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2010 | 1983 | 0.060 |
Why?
|
| Breast Density | 2 | 2017 | 36 | 0.060 |
Why?
|
| Child Development | 1 | 2007 | 167 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2005 | 78 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2006 | 211 | 0.060 |
Why?
|
| Microwaves | 1 | 2005 | 36 | 0.060 |
Why?
|
| Abortion, Spontaneous | 1 | 2006 | 66 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2006 | 234 | 0.060 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 82 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 414 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 603 | 0.060 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 3 | 1995 | 20 | 0.060 |
Why?
|
| Choice Behavior | 1 | 2006 | 160 | 0.060 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 9 | 0.060 |
Why?
|
| Postpartum Period | 2 | 2018 | 149 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1227 | 0.060 |
Why?
|
| Discriminant Analysis | 2 | 2007 | 67 | 0.060 |
Why?
|
| Ethanol | 2 | 2017 | 252 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2006 | 222 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2005 | 86 | 0.060 |
Why?
|
| Culture | 1 | 2005 | 53 | 0.060 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 200 | 0.060 |
Why?
|
| Smoking | 2 | 2019 | 625 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2007 | 322 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2015 | 520 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 2006 | 262 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 740 | 0.060 |
Why?
|
| Software | 3 | 2017 | 669 | 0.060 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2014 | 37 | 0.060 |
Why?
|
| North America | 3 | 2011 | 188 | 0.060 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2015 | 35 | 0.060 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2015 | 33 | 0.060 |
Why?
|
| Peptide Synthases | 1 | 2003 | 12 | 0.060 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2023 | 10 | 0.060 |
Why?
|
| Vincristine | 2 | 1996 | 111 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 156 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2014 | 72 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1180 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2018 | 466 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 63 | 0.050 |
Why?
|
| International Cooperation | 2 | 2014 | 127 | 0.050 |
Why?
|
| Prednisone | 2 | 1996 | 255 | 0.050 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2002 | 18 | 0.050 |
Why?
|
| Genetic Linkage | 2 | 2004 | 624 | 0.050 |
Why?
|
| DNA Primers | 6 | 2007 | 543 | 0.050 |
Why?
|
| Metabolomics | 1 | 2023 | 76 | 0.050 |
Why?
|
| Hormones | 1 | 2023 | 139 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2002 | 84 | 0.050 |
Why?
|
| Counseling | 1 | 2023 | 166 | 0.050 |
Why?
|
| International Agencies | 2 | 2014 | 34 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2010 | 3765 | 0.050 |
Why?
|
| Genes, Dominant | 2 | 2004 | 117 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2021 | 32 | 0.050 |
Why?
|
| Sendai virus | 1 | 2021 | 8 | 0.050 |
Why?
|
| Respirovirus Infections | 1 | 2021 | 12 | 0.050 |
Why?
|
| Retinoblastoma Protein | 1 | 2001 | 64 | 0.050 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 50 | 0.050 |
Why?
|
| DNA Damage | 2 | 2019 | 373 | 0.050 |
Why?
|
| Canada | 2 | 2015 | 208 | 0.050 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 77 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 110 | 0.050 |
Why?
|
| Protective Factors | 1 | 2020 | 23 | 0.050 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 82 | 0.050 |
Why?
|
| Acid Anhydride Hydrolases | 2 | 2011 | 13 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 331 | 0.050 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 13 | 0.050 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2020 | 73 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 27 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 371 | 0.040 |
Why?
|
| Serine | 1 | 2020 | 105 | 0.040 |
Why?
|
| Genetic Research | 2 | 1997 | 18 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2023 | 460 | 0.040 |
Why?
|
| Minichromosome Maintenance Complex Component 2 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Phylogeny | 2 | 2016 | 1196 | 0.040 |
Why?
|
| Protein Domains | 1 | 2020 | 135 | 0.040 |
Why?
|
| Melanoma | 2 | 1995 | 471 | 0.040 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2019 | 4 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2020 | 69 | 0.040 |
Why?
|
| Interferon-alpha | 2 | 1998 | 214 | 0.040 |
Why?
|
| Computers | 1 | 2000 | 111 | 0.040 |
Why?
|
| Bronchi | 1 | 2001 | 230 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 854 | 0.040 |
Why?
|
| Fanconi Anemia | 1 | 2019 | 9 | 0.040 |
Why?
|
| Glutathione Transferase | 2 | 2000 | 112 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 195 | 0.040 |
Why?
|
| Africa, Northern | 1 | 2019 | 5 | 0.040 |
Why?
|
| Glutathione | 2 | 2000 | 108 | 0.040 |
Why?
|
| Middle East | 1 | 2019 | 18 | 0.040 |
Why?
|
| Biophysical Phenomena | 1 | 2000 | 124 | 0.040 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2019 | 18 | 0.040 |
Why?
|
| Biophysics | 1 | 2000 | 153 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 149 | 0.040 |
Why?
|
| Colonic Polyps | 1 | 2000 | 132 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2019 | 33 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 358 | 0.040 |
Why?
|
| HIV | 1 | 2019 | 48 | 0.040 |
Why?
|
| Data Mining | 1 | 2019 | 44 | 0.040 |
Why?
|
| Menopause | 1 | 2019 | 76 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2019 | 135 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2019 | 102 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2019 | 66 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2018 | 5 | 0.040 |
Why?
|
| China | 1 | 2019 | 235 | 0.040 |
Why?
|
| Population Health | 1 | 2019 | 33 | 0.040 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1999 | 21 | 0.040 |
Why?
|
| Palpation | 1 | 2018 | 18 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 1999 | 30 | 0.040 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 1999 | 117 | 0.040 |
Why?
|
| Codon | 1 | 1999 | 123 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2018 | 70 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2007 | 2887 | 0.040 |
Why?
|
| Genomic Library | 2 | 1995 | 33 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2000 | 591 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1998 | 36 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 368 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 383 | 0.040 |
Why?
|
| Penetrance | 1 | 2018 | 45 | 0.040 |
Why?
|
| Biological Transport | 2 | 2010 | 401 | 0.040 |
Why?
|
| Models, Biological | 2 | 2008 | 1765 | 0.040 |
Why?
|
| Receptors, Notch | 1 | 2018 | 126 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 397 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 78 | 0.040 |
Why?
|
| Ultrasonography, Mammary | 1 | 2018 | 83 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2018 | 173 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 427 | 0.040 |
Why?
|
| American Cancer Society | 1 | 1997 | 13 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2009 | 1607 | 0.040 |
Why?
|
| Physical Examination | 1 | 2018 | 149 | 0.040 |
Why?
|
| Genes, bcl-2 | 1 | 1997 | 15 | 0.040 |
Why?
|
| Asia | 1 | 2017 | 102 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1998 | 79 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 1998 | 69 | 0.040 |
Why?
|
| Glycoproteins | 1 | 1999 | 235 | 0.040 |
Why?
|
| Autoantibodies | 1 | 1999 | 270 | 0.040 |
Why?
|
| bcl-X Protein | 1 | 1997 | 53 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2020 | 759 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2017 | 14 | 0.040 |
Why?
|
| Purines | 1 | 1997 | 93 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 40 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2018 | 230 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 433 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2014 | 1532 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1997 | 243 | 0.040 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 33 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 1997 | 20 | 0.040 |
Why?
|
| DNA | 2 | 2001 | 1311 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 952 | 0.040 |
Why?
|
| Organizational Policy | 1 | 1997 | 55 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 81 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2019 | 236 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 1091 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2019 | 231 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2017 | 93 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2009 | 2766 | 0.030 |
Why?
|
| Federal Government | 1 | 1996 | 29 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 811 | 0.030 |
Why?
|
| Empirical Research | 1 | 1996 | 19 | 0.030 |
Why?
|
| DNA, Intergenic | 1 | 2016 | 28 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2017 | 92 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2016 | 106 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1998 | 174 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2020 | 400 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 310 | 0.030 |
Why?
|
| Cyclophilins | 1 | 2016 | 8 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 108 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1999 | 250 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2017 | 104 | 0.030 |
Why?
|
| tRNA Methyltransferases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 1997 | 114 | 0.030 |
Why?
|
| Decision Making | 2 | 2016 | 669 | 0.030 |
Why?
|
| Sexism | 1 | 2016 | 54 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 1996 | 23 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1996 | 101 | 0.030 |
Why?
|
| Organizations, Nonprofit | 1 | 2015 | 8 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2016 | 78 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 258 | 0.030 |
Why?
|
| Aspirin | 1 | 2017 | 161 | 0.030 |
Why?
|
| Affect | 1 | 2018 | 389 | 0.030 |
Why?
|
| Cisplatin | 2 | 2008 | 598 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1998 | 305 | 0.030 |
Why?
|
| Income | 1 | 2016 | 85 | 0.030 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2015 | 24 | 0.030 |
Why?
|
| Critical Care | 1 | 1999 | 384 | 0.030 |
Why?
|
| Cosmids | 1 | 1995 | 22 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 195 | 0.030 |
Why?
|
| Functional Laterality | 2 | 2006 | 200 | 0.030 |
Why?
|
| Interphase | 1 | 1995 | 35 | 0.030 |
Why?
|
| Neoplasms, Experimental | 2 | 2013 | 269 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 1995 | 21 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 1995 | 30 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2019 | 417 | 0.030 |
Why?
|
| Reference Standards | 2 | 2010 | 144 | 0.030 |
Why?
|
| Nucleotides | 1 | 2015 | 98 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 116 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2015 | 155 | 0.030 |
Why?
|
| Methotrexate | 2 | 1997 | 243 | 0.030 |
Why?
|
| Cetuximab | 1 | 2015 | 115 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 6 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 1995 | 262 | 0.030 |
Why?
|
| Foundations | 1 | 2014 | 15 | 0.030 |
Why?
|
| Government Agencies | 1 | 2014 | 11 | 0.030 |
Why?
|
| Pain Management | 1 | 2015 | 143 | 0.030 |
Why?
|
| Monocytes | 1 | 1995 | 221 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 216 | 0.030 |
Why?
|
| Cell Membrane | 2 | 2007 | 677 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 234 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2014 | 124 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2013 | 63 | 0.030 |
Why?
|
| Cognition | 1 | 2018 | 579 | 0.030 |
Why?
|
| Ethics, Research | 1 | 2014 | 52 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2013 | 35 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 2392 | 0.030 |
Why?
|
| Endothelium | 1 | 2013 | 58 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 21 | 0.030 |
Why?
|
| Telomere | 1 | 1994 | 119 | 0.030 |
Why?
|
| Claudins | 1 | 2013 | 33 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 44 | 0.030 |
Why?
|
| Protein Stability | 1 | 2013 | 101 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 21 | 0.030 |
Why?
|
| Caloric Restriction | 1 | 2013 | 14 | 0.030 |
Why?
|
| Suppression, Genetic | 1 | 2013 | 30 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2013 | 124 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2013 | 98 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 272 | 0.030 |
Why?
|
| Translating | 1 | 2012 | 18 | 0.030 |
Why?
|
| Haiti | 1 | 2012 | 22 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 1995 | 248 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2013 | 81 | 0.030 |
Why?
|
| Oxidants | 1 | 2013 | 86 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 140 | 0.030 |
Why?
|
| Volunteers | 1 | 2012 | 22 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2013 | 132 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 1992 | 45 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2013 | 80 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1996 | 644 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 2012 | 28 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 280 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 244 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 114 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2013 | 256 | 0.030 |
Why?
|
| Risk Management | 1 | 2012 | 44 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2012 | 270 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1992 | 82 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 263 | 0.030 |
Why?
|
| Rural Population | 1 | 2013 | 147 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 426 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 184 | 0.020 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2011 | 9 | 0.020 |
Why?
|
| Sirolimus | 1 | 2013 | 162 | 0.020 |
Why?
|
| Endonucleases | 1 | 2011 | 23 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2011 | 40 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 1074 | 0.020 |
Why?
|
| Fats | 1 | 2011 | 12 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 158 | 0.020 |
Why?
|
| Anthracyclines | 1 | 2011 | 38 | 0.020 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2011 | 14 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 283 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2011 | 42 | 0.020 |
Why?
|
| High-Temperature Requirement A Serine Peptidase 1 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Antioxidants | 1 | 2013 | 226 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 268 | 0.020 |
Why?
|
| Rural Health | 1 | 2011 | 21 | 0.020 |
Why?
|
| Matched-Pair Analysis | 2 | 2002 | 40 | 0.020 |
Why?
|
| Air Pollutants | 1 | 2013 | 96 | 0.020 |
Why?
|
| HapMap Project | 1 | 2011 | 47 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 168 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.020 |
Why?
|
| Mesothelioma | 1 | 1994 | 320 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2011 | 189 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 646 | 0.020 |
Why?
|
| Proteins | 1 | 1996 | 786 | 0.020 |
Why?
|
| Sodium-Bicarbonate Symporters | 1 | 2010 | 7 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 86 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 178 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 341 | 0.020 |
Why?
|
| Ascites | 1 | 1991 | 56 | 0.020 |
Why?
|
| Species Specificity | 2 | 2007 | 685 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2011 | 84 | 0.020 |
Why?
|
| Palliative Care | 1 | 2013 | 264 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 161 | 0.020 |
Why?
|
| Stem Cells | 1 | 2013 | 376 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1992 | 899 | 0.020 |
Why?
|
| Perception | 1 | 2012 | 179 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2010 | 63 | 0.020 |
Why?
|
| Oils | 1 | 2010 | 6 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1990 | 44 | 0.020 |
Why?
|
| Injections | 1 | 2010 | 116 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1990 | 49 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 310 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2012 | 284 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1130 | 0.020 |
Why?
|
| Thigh | 1 | 1990 | 39 | 0.020 |
Why?
|
| Glucose | 1 | 2013 | 629 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2010 | 43 | 0.020 |
Why?
|
| Bleomycin | 1 | 1990 | 103 | 0.020 |
Why?
|
| MRE11 Homologue Protein | 1 | 2009 | 2 | 0.020 |
Why?
|
| Leucovorin | 1 | 1990 | 222 | 0.020 |
Why?
|
| Endodeoxyribonucleases | 1 | 2009 | 11 | 0.020 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2009 | 8 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 199 | 0.020 |
Why?
|
| Arthralgia | 1 | 2009 | 39 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 300 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 808 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 283 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 1990 | 265 | 0.020 |
Why?
|
| Angiopoietins | 1 | 2009 | 6 | 0.020 |
Why?
|
| Cytarabine | 1 | 1990 | 219 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 269 | 0.020 |
Why?
|
| RNA Helicases | 1 | 2009 | 35 | 0.020 |
Why?
|
| Family Practice | 1 | 2009 | 83 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2010 | 277 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1990 | 128 | 0.020 |
Why?
|
| Thiones | 2 | 2000 | 10 | 0.020 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2009 | 83 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2001 | 173 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 88 | 0.020 |
Why?
|
| Carcinoma, Medullary | 1 | 2008 | 9 | 0.020 |
Why?
|
| Symporters | 1 | 2009 | 108 | 0.020 |
Why?
|
| Thiophenes | 2 | 2000 | 43 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2008 | 42 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 2008 | 45 | 0.020 |
Why?
|
| Hawaii | 1 | 2007 | 25 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 476 | 0.020 |
Why?
|
| Leucine | 1 | 2007 | 60 | 0.020 |
Why?
|
| Threonine | 1 | 2007 | 35 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 166 | 0.020 |
Why?
|
| Isoleucine | 1 | 2007 | 19 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2008 | 100 | 0.020 |
Why?
|
| Etoposide | 1 | 2008 | 206 | 0.020 |
Why?
|
| Histidine | 1 | 2007 | 56 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 1534 | 0.020 |
Why?
|
| Proline | 1 | 2007 | 55 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 2007 | 36 | 0.020 |
Why?
|
| Tyrosine | 1 | 2007 | 133 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2007 | 17 | 0.020 |
Why?
|
| Aurora Kinase A | 1 | 2007 | 11 | 0.020 |
Why?
|
| Health Status | 1 | 2009 | 371 | 0.020 |
Why?
|
| Fractals | 1 | 2007 | 42 | 0.020 |
Why?
|
| Carcinoma, Ductal | 1 | 2007 | 18 | 0.020 |
Why?
|
| Cyclin A1 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2006 | 3 | 0.020 |
Why?
|
| MSX1 Transcription Factor | 1 | 2006 | 3 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2006 | 12 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2011 | 515 | 0.020 |
Why?
|
| Cyclin A | 1 | 2006 | 29 | 0.020 |
Why?
|
| Cathepsins | 1 | 2006 | 21 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2006 | 28 | 0.020 |
Why?
|
| X-Rays | 1 | 2007 | 137 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 1394 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 2006 | 15 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 740 | 0.020 |
Why?
|
| Aging | 1 | 2011 | 726 | 0.020 |
Why?
|
| Israel | 1 | 2006 | 57 | 0.020 |
Why?
|
| Keratin-5 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Keratin-6 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 958 | 0.020 |
Why?
|
| Keratins | 1 | 2006 | 63 | 0.020 |
Why?
|
| Neprilysin | 1 | 2006 | 41 | 0.020 |
Why?
|
| Infant | 2 | 2007 | 3187 | 0.020 |
Why?
|
| Thionucleosides | 2 | 1997 | 8 | 0.020 |
Why?
|
| Sample Size | 1 | 2006 | 125 | 0.020 |
Why?
|
| Deoxyadenosines | 2 | 1997 | 23 | 0.020 |
Why?
|
| Health Policy | 1 | 2007 | 188 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2007 | 203 | 0.020 |
Why?
|
| Menstruation | 1 | 2005 | 35 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 434 | 0.020 |
Why?
|
| Genome | 1 | 2008 | 391 | 0.020 |
Why?
|
| CCCTC-Binding Factor | 1 | 2004 | 18 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2004 | 49 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 435 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2006 | 261 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1995 | 135 | 0.010 |
Why?
|
| Body Water | 1 | 2004 | 35 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2006 | 355 | 0.010 |
Why?
|
| Chromosomes | 1 | 2004 | 98 | 0.010 |
Why?
|
| Transcription Factor AP-2 | 1 | 2004 | 14 | 0.010 |
Why?
|
| Actins | 1 | 2006 | 462 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 692 | 0.010 |
Why?
|
| Physical Chromosome Mapping | 1 | 2001 | 27 | 0.010 |
Why?
|
| 5' Untranslated Regions | 1 | 2001 | 52 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2001 | 258 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2001 | 121 | 0.010 |
Why?
|
| Scotland | 1 | 2000 | 5 | 0.010 |
Why?
|
| Rectum | 1 | 2000 | 148 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2000 | 161 | 0.010 |
Why?
|
| beta 2-Glycoprotein I | 1 | 1999 | 6 | 0.010 |
Why?
|
| Gangrene | 1 | 1999 | 7 | 0.010 |
Why?
|
| Scleroderma, Localized | 1 | 1999 | 9 | 0.010 |
Why?
|
| Hematoma, Subdural | 1 | 1999 | 25 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1999 | 78 | 0.010 |
Why?
|
| Leg | 1 | 1999 | 140 | 0.010 |
Why?
|
| Cattle | 1 | 1999 | 378 | 0.010 |
Why?
|
| Fingers | 1 | 1999 | 69 | 0.010 |
Why?
|
| Medical History Taking | 1 | 1998 | 82 | 0.010 |
Why?
|
| Azaserine | 1 | 1997 | 4 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 1998 | 42 | 0.010 |
Why?
|
| Guanine | 1 | 1999 | 207 | 0.010 |
Why?
|
| Antimalarials | 1 | 1997 | 20 | 0.010 |
Why?
|
| Societies | 1 | 1997 | 16 | 0.010 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 1997 | 15 | 0.010 |
Why?
|
| Methionine | 1 | 1997 | 67 | 0.010 |
Why?
|
| Genetics | 1 | 1997 | 24 | 0.010 |
Why?
|
| Cell Count | 1 | 1997 | 199 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 1996 | 6 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 28 | 0.010 |
Why?
|
| Professional Competence | 1 | 1997 | 69 | 0.010 |
Why?
|
| Ischemia | 1 | 1999 | 253 | 0.010 |
Why?
|
| Leukemia, T-Cell | 1 | 1995 | 17 | 0.010 |
Why?
|
| Leukemia, B-Cell | 1 | 1995 | 23 | 0.010 |
Why?
|
| Thrombosis | 1 | 1999 | 302 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1995 | 88 | 0.010 |
Why?
|
| Metaphase | 1 | 1995 | 24 | 0.010 |
Why?
|
| Ploidies | 1 | 1995 | 41 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1999 | 431 | 0.010 |
Why?
|
| Biological Availability | 1 | 1995 | 91 | 0.010 |
Why?
|
| Genes, Overlapping | 1 | 1994 | 4 | 0.010 |
Why?
|
| Area Under Curve | 1 | 1995 | 338 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1994 | 71 | 0.010 |
Why?
|
| Adenosine | 1 | 1997 | 240 | 0.010 |
Why?
|
| Crossing Over, Genetic | 1 | 1994 | 33 | 0.010 |
Why?
|
| Gene Library | 1 | 1994 | 132 | 0.010 |
Why?
|
| Cellular Senescence | 1 | 1995 | 100 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1995 | 666 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 977 | 0.010 |
Why?
|
| Tetrahydrofolates | 1 | 1993 | 13 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1995 | 151 | 0.010 |
Why?
|
| Interferon-beta | 1 | 1994 | 126 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1992 | 47 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 147 | 0.010 |
Why?
|
| Rats | 1 | 1997 | 4048 | 0.010 |
Why?
|
| Blast Crisis | 1 | 1990 | 37 | 0.010 |
Why?
|
| Burkitt Lymphoma | 1 | 1990 | 32 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 1990 | 111 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1990 | 217 | 0.010 |
Why?
|
| Lymphoma, Follicular | 1 | 1990 | 73 | 0.010 |
Why?
|
| Biological Evolution | 1 | 1994 | 970 | 0.000 |
Why?
|